Biosimilars Dodge Bullet As High Court Upholds ACA

By Jeff Overley (June 28, 2012, 12:52 PM EDT) -- Manufacturers of biologic drugs breathed a sigh of relief Thursday after the U.S. Supreme Court narrowly upheld the Obama administration's health reform law, which includes revolutionary changes to the industry's approval process, experts said.

One of the law's most relevant provisions for pharmaceutical firms created an approval pathway for biosimilars, the generic equivalents of high-priced brand-name biologics. Many manufacturers had anxiously awaited the high court's ruling, fearing it could erase that authorization and set the industry back months or years.

"This is a huge victory for the people who lobbied to institute that pathway," said William J. Simmons, an associate in...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!